Construction of human BMP2-IRES-HIF1αmu adenovirus expression vector and its expression in mesenchymal stem cells

Molecular Medicine Reports

Volumn 7, Issue 2, 2013, Pages 659-663

  Liu, Danping ^a   Hu, Liang ^b   Zhang, Zheng ^a   Li, Quan Ying ^a   Wang, Guoxian ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b First People's Hospital of Jingmen   (China)

Author keywords

Bone marrow mesenchymal stem cells; Bone morphogenetic protein 2; Hypoxia inducible factor 1

Indexed keywords

ADENOVIRUS VECTOR; BONE MORPHOGENETIC PROTEIN 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; MESENCHYMAL STEM CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CELLS, CULTURED; GENETIC VECTORS; HEK293 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MESENCHYMAL STROMAL CELLS; MUTATION; RABBITS; RNA, MESSENGER; TRANSFECTION;

EID: 84873846739     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1237     Document Type: Article

References (20)

1. Jorgensen NR, Henriksen Z, Sorensen OH and Civitelli R: Dexamethasone, BMP-2, and 1, 25-dihydroxyvitamin D enhance a more differentiated osteoblast phenotype: validation of an in vitro model for human bone marrow-derived primary osteoblasts. Steroids 69: 219-226, 2004.
2. Shin JH, Kim KH, Kim SH, et al: Ex vivo bone morphogenetic protein-2 gene delivery using gingival fibroblasts promotes bone regeneration in rats. J Clin Periodontol 37: 305-311, 2010.
3. Cheng H, Jiang W, Phillips FM, et al: Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). Bone Joint Surg Am 85: 1544-1552, 2003.
4. Wan C, Gilbert SR, Wang Y, et al: Activation of the hypoxia-inducible factor-1-alpha pathway accelerates. Proc Nat Acad Sci U S A 105: 686-691, 2008.
5. Hua Z, Nicola JM, Margaret TM and Simons J: Nuclear expression of hypoxia-inducible factor 1alpha protein is heterogeneous in human malignantcells under normoxic conditions. Cancer Lett 181: 233, 2002.
6. Wang Y, Wan C, Deng L, et al: The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 117: 1616-1626, 2007.
7. Giaccia A, Siim BG and Johnson RS: HIF-1 as a target for drug development. Nat Rev Drug Discov 2: 803-811, 2003.
8. Diab T, Pritchard EM, Uhrig BA, Boerckel JD, Kaplan DL and Guldberg RE: A silk hydrogel-based delivery system of bone morphogenetic protein for the treatment of large bone defects. J Mech Behav Biomed Mater 11: 123-131, 2012.
9. Wigner NA, Luderer HF, Cox MK, Sooy K, Gerstenfeld LC and Demay MB: Acute phosphate restriction leads to impaired fracture healing and resistance to BMP-2. J Bone Miner Res 25: 724-733, 2010.
10. Kim TH, Oh SH, Na SY, Chun SY and Lee JH: Effect of biological/physical stimulation on guided bone regeneration through asymmetrically porous membrane. J Biomed Mater Res A 100: 1512-1520, 2012.
11. Chang SC, Lin TM, Chung HY, et al: Large-scale bicortical skull bone regeneration using ex vivo replication-defective adenoviral-mediated bone morphogenetic protein-2 gene-transferred bone marrow stromal cells and composite biomaterials. Neurosurgery 65: 75-81, 2009.
12. Liu Y, Lu Y, Tian X, et al: Fragmental bone regeneration using an rhBMP-2-loaded gelatin/nanohydroxyapatite/fibrin scaffold in a rabbit model. Biomaterials 30: 6276-6285, 2009.
13. Baltzer AW, Ostapczuk MS, Stosch D and Granrath M: The use of recombinant human bone morphogenetic protein-2 for the treatment of a delayed union following femoral neck open-wedge osteotomy. Orthop Rev (Pavia) 4: e4, 2012.
14. Kanczler JM, Ginty PJ, White L, et al: The effect of the delivery of vascular endothelial growth factor and bone morphogenic protein-2 to osteoprogenitor cell populations on bone formation. Biomaterials 31: 1242-1250, 2010.
15. Kang SW, Bae JH, Park SA, et al: Combination therapy with BMP-2 and BMSCs enhances bone healing efficacy of PCL scaffold fabricated using the 3D plotting system in a large fragmental defect model. Biotechnol Lett 34: 1375-1384, 2012.
16. Simon F, Bockhorn M, Praha C, et al: Deregulation of HIF1-alpha and hypoxia- regulated pathways in hepatocellular carcinoma and corresponding non-malignant liver tissue-influence of a modulated host stroma on the prognosis of HCC. Langenbecks Arch Surg 395: 395-405, 2010.
17. Lando D, Peet DJ, Whelan DA, Gorman JJ and Whitelaw ML: Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295: 858-861, 2002.
18. Lim W, Cho J, Kwon HY, Park Y, Rhyu MR and Lee Y: Hypoxia-inducible factor 1 alpha activates and is inhibited by unoccupied estrogen receptor beta. FEBS Lett 583: 1314-1318, 2009.
19. Elson DA, Thurston G, Huang LE, et al: Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev 15: 2520-2532, 2001.
20. Liu DP, Wang GX, Hu L and Li C: Construction of adenovirus-mediated eukaryotic expression vector co-expressing mutant hypoxia-inducible factor-1 alpha target protein and humanized Renilla reniformis green fluorescent protein reporter molecule under normoxic conditions. J Clin Rehab Tiss Eng Res 14: 3787-3792, 2010.